Wecome Pharmaceutical Co Ltd (300878) - Total Liabilities
Based on the latest financial reports, Wecome Pharmaceutical Co Ltd (300878) has total liabilities worth CN¥458.37 Million CNY (≈ $67.07 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Wecome Pharmaceutical Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Wecome Pharmaceutical Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Wecome Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Wecome Pharmaceutical Co Ltd's balance sheet.
Wecome Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Wecome Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kim Loong Resources Bhd
KLSE:5027
|
Malaysia | RM422.56 Million |
|
SunCoke Energy Inc
NYSE:SXC
|
USA | $1.21 Billion |
|
Qingdao Kutesmart Co Ltd
SHE:300840
|
China | CN¥361.17 Million |
|
Shanghai Hugong Elec(Group)
SHG:603131
|
China | CN¥430.66 Million |
|
Beijing SDL Technology Co Ltd
SHE:002658
|
China | CN¥391.46 Million |
|
Surya Citra Media Tbk
JK:SCMA
|
Indonesia | Rp3.02 Trillion |
|
Chengdu Bright Eye Hospital Co. Ltd.
SHE:301239
|
China | CN¥2.60 Billion |
|
ZheJiang RIFA Digital Precision Machinery Co Ltd
SHE:002520
|
China | CN¥1.54 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Wecome Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Wecome Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Wecome Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Wecome Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual total liabilities of Wecome Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥478.50 Million ≈ $70.02 Million |
-25.14% |
| 2023-12-31 | CN¥639.23 Million ≈ $93.54 Million |
+27.27% |
| 2022-12-31 | CN¥502.25 Million ≈ $73.50 Million |
+76.67% |
| 2021-12-31 | CN¥284.28 Million ≈ $41.60 Million |
+16.32% |
| 2020-12-31 | CN¥244.39 Million ≈ $35.76 Million |
-31.35% |
| 2019-12-31 | CN¥356.02 Million ≈ $52.10 Million |
+43.97% |
| 2018-12-31 | CN¥247.29 Million ≈ $36.19 Million |
+42.38% |
| 2017-12-31 | CN¥173.68 Million ≈ $25.42 Million |
+66.61% |
| 2016-12-31 | CN¥104.25 Million ≈ $15.25 Million |
+13.51% |
| 2015-12-31 | CN¥91.84 Million ≈ $13.44 Million |
-3.14% |
| 2014-12-31 | CN¥94.82 Million ≈ $13.88 Million |
+30.28% |
| 2013-12-31 | CN¥72.78 Million ≈ $10.65 Million |
-- |
About Wecome Pharmaceutical Co Ltd
Zhejiang Wecome Pharmaceutical Company Limited engages in the research and development, production, and sale of modern traditional Chinese and western medicine in China. The company offers products in various forms, including hard capsules, tablets, granules, soft capsules, pills, and other dosage forms. It also operates the retail of pharmaceutical commercial products. The company was formerly k… Read more